drugset / Trial / NCT05267613
Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
Phase 3
Active not recruiting
53 enrolled
AstraZeneca
CISCRP · collabCalyx · collabIQVIA RDS Inc. · collabLaboratory Corporation of America · collabLittle Journey Ltd. · collabMedidata Solutions · collabQuipment Inc. · collabThermo Fisher Scientific, Inc · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of the study is to compare the safety and efficacy of two doses of Nexium in maintaining healing of erosive esophagitis in patients 1 to 11 years of age.
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-08-14
- Completion
- 2026-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Esomeprazole | Small molecule | 5 mg | Oral |
| Comparator | Esomeprazole | Small molecule | 10 mg | Oral |